Novartis Investigative site

St Leonards 2065

1 studies enrolling now · 10 studies all time

What they study most

Alport Syndrome, Chronic Myelogenous Leukemia, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Fallopian Tube Cancer, Focal Segmental Glomerulosclerosis, IgA Nephropathy, Immunoglobulin A Nephropathy, Myelogenous Leukemia, Osteoarthritis, Osteoarthritis, Knee, Ovarian Cancer

Studies at this site

• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Recruiting now
• Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) — Running, not enrolling
• Atrasentan in Patients With Proteinuric Glomerular Diseases — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis — Stopped early
• A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA — Stopped early
• Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer — Completed
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia — Completed
• Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period — Completed
• Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Stopped early